JP2013518049A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518049A5 JP2013518049A5 JP2012550135A JP2012550135A JP2013518049A5 JP 2013518049 A5 JP2013518049 A5 JP 2013518049A5 JP 2012550135 A JP2012550135 A JP 2012550135A JP 2012550135 A JP2012550135 A JP 2012550135A JP 2013518049 A5 JP2013518049 A5 JP 2013518049A5
- Authority
- JP
- Japan
- Prior art keywords
- lactide
- intraluminal implant
- therapeutic agent
- implant according
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007943 implant Substances 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims 5
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 3
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical group CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims 3
- 229960002470 bimatoprost Drugs 0.000 claims 3
- 238000002513 implantation Methods 0.000 claims 3
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 210000002159 anterior chamber Anatomy 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29766010P | 2010-01-22 | 2010-01-22 | |
| US61/297,660 | 2010-01-22 | ||
| PCT/US2011/021971 WO2011091205A2 (en) | 2010-01-22 | 2011-01-21 | Intracameral sustained release therapeutic agent implants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518049A JP2013518049A (ja) | 2013-05-20 |
| JP2013518049A5 true JP2013518049A5 (enExample) | 2014-03-06 |
| JP5809169B2 JP5809169B2 (ja) | 2015-11-10 |
Family
ID=43795202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012550135A Active JP5809169B2 (ja) | 2010-01-22 | 2011-01-21 | 治療薬持続放出型腔内インプラント |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US8647659B2 (enExample) |
| EP (3) | EP3085358B1 (enExample) |
| JP (1) | JP5809169B2 (enExample) |
| KR (4) | KR102337046B1 (enExample) |
| CN (2) | CN107184544A (enExample) |
| AU (1) | AU2011207281B2 (enExample) |
| BR (1) | BR112012018134B1 (enExample) |
| CA (1) | CA2787514C (enExample) |
| DK (2) | DK3085358T3 (enExample) |
| ES (2) | ES2561083T3 (enExample) |
| RU (1) | RU2565445C2 (enExample) |
| WO (1) | WO2011091205A2 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US8968396B2 (en) | 2007-07-23 | 2015-03-03 | Powervision, Inc. | Intraocular lens delivery systems and methods of use |
| US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| JP5937004B2 (ja) | 2009-05-18 | 2016-06-22 | ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ | 薬剤溶出眼内インプラント |
| WO2012071476A2 (en) | 2010-11-24 | 2012-05-31 | David Haffner | Drug eluting ocular implant |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| EP2451503B1 (en) | 2009-07-09 | 2018-10-24 | Ivantis, Inc. | Ocular implants and methods for delivering ocular implants into the eye |
| CA2766131C (en) | 2009-07-09 | 2017-10-24 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
| KR102337046B1 (ko) | 2010-01-22 | 2021-12-08 | 알러간, 인코포레이티드 | 전방내 서방성 치료제 이식물 |
| WO2011106435A2 (en) | 2010-02-23 | 2011-09-01 | Powervision, Inc. | Fluid for accommodating intraocular lenses |
| WO2012149278A1 (en) | 2011-04-29 | 2012-11-01 | Allergan, Inc. | Sustained release latanoprost implant |
| US10245178B1 (en) * | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
| US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
| US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
| WO2014066653A1 (en) * | 2012-10-26 | 2014-05-01 | Allergan, Inc. | Ketorolac-containing sustained release intraocular drug delivery systems |
| WO2014066658A1 (en) * | 2012-10-26 | 2014-05-01 | Allergan, Inc. | Ketorolac-containing sustained release drug delivery systems |
| WO2014085450A1 (en) | 2012-11-28 | 2014-06-05 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
| JP2016512532A (ja) * | 2013-03-14 | 2016-04-28 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 硝子体内および前房内経路を通じて眼圧および眼疾患を治療するためのα−２アドレナリン作動薬 |
| WO2014145562A1 (en) | 2013-03-15 | 2014-09-18 | Powervision, Inc. | Intraocular lens storage and loading devices and methods of use |
| BR122019025507B1 (pt) * | 2013-03-15 | 2021-01-12 | Allergan, Inc. | implante intraocular biodegradável contendo prostamida e seu uso |
| CN105188666A (zh) | 2013-04-01 | 2015-12-23 | 阿勒根公司 | 用于持续的眼内释放的微球药物递送系统 |
| TR201802759T4 (tr) * | 2013-10-31 | 2018-03-21 | Allergan Inc | Prostamid içeren intraoküler implantlar ve kullanım yöntemleri. |
| CN106132397A (zh) * | 2013-12-06 | 2016-11-16 | 恩维希亚治疗股份有限公司 | 用于治疗眼部疾病的前房内植入物 |
| EP3148491B1 (en) | 2014-05-29 | 2020-07-01 | Glaukos Corporation | Implants with controlled drug delivery features and manufacturing method for said implants |
| WO2016011056A1 (en) | 2014-07-14 | 2016-01-21 | Ivantis, Inc. | Ocular implant delivery system and method |
| ES2900025T3 (es) | 2014-09-06 | 2022-03-15 | Integral Biosystems Llc | Procedimientos y composiciones biocompatibles para lograr la liberación mantenida de fármaco en el ojo |
| EP3302382A4 (en) | 2015-05-29 | 2019-02-20 | Allergan, Inc. | IMPLANT FOR THE TREATMENT OF OCULAR DISEASE |
| WO2016200688A1 (en) * | 2015-06-06 | 2016-12-15 | Cloudbreak Therapeutics, Llc | Compositions and methods for treating pterygium |
| CN108135470B (zh) | 2015-08-14 | 2021-03-09 | 伊万提斯公司 | 具有压力传感器和输送系统的眼部植入物 |
| US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| US11458041B2 (en) | 2015-10-08 | 2022-10-04 | Ocular Therapeutix, Inc. | Punctal plug and bioadhesives |
| US11938058B2 (en) | 2015-12-15 | 2024-03-26 | Alcon Inc. | Ocular implant and delivery system |
| PT109154B (pt) * | 2016-02-12 | 2019-11-05 | Univ De Coimbra | Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos |
| JP7003110B2 (ja) | 2016-04-20 | 2022-01-20 | ドーズ メディカル コーポレーション | 生体吸収性眼球薬物送達デバイス |
| KR102408596B1 (ko) | 2016-06-02 | 2022-06-13 | 에이디에스 테라퓨틱스 엘엘씨 | 비정상적 신생혈관이 있는 안구 질환 치료를 위한, 닌테다닙을 사용하는 조성물 및 방법 |
| JP7430529B2 (ja) | 2016-09-23 | 2024-02-13 | インセプト・リミテッド・ライアビリティ・カンパニー | 前房内薬物送達デポ |
| EP4046609B1 (en) | 2016-09-30 | 2025-02-26 | Mati Therapeutics Inc. | Ophthalmic drug sustained release formulation and uses thereof |
| WO2018169967A1 (en) | 2017-03-14 | 2018-09-20 | Allergan, Inc. | Acorafloxacin in treating ocular infections |
| EP3658149B1 (en) | 2017-07-25 | 2021-11-10 | Allergan, Inc. | Solid complex comprising (z)-7-((1r,2r,3r,5s)-2-((s,e)-5-(2,5-dichlorothiophen-3-yl)-3-hydroxypent-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enamide, preparation and uses thereof |
| US20190192341A1 (en) * | 2017-11-09 | 2019-06-27 | Allergan, Inc. | Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of Effect |
| EP4371535A3 (en) | 2018-02-22 | 2024-08-14 | Alcon Inc. | Ocular implant |
| US20210121534A1 (en) * | 2018-06-19 | 2021-04-29 | Cella Therapeutics, Llc | Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension |
| US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
| SG11202101730SA (en) | 2018-08-21 | 2021-03-30 | Allergan Inc | The use of alpha-2-adrenergic receptor agonists for improving vision |
| WO2020047144A2 (en) * | 2018-08-30 | 2020-03-05 | Liu Yunxiang | Ophthalmic formulations, process for preparing the same and method for administering the same |
| CA3166738A1 (en) | 2020-02-06 | 2021-08-12 | Charles D. Blizzard | Travoprost compositions and methods for treating ocular diseases |
| WO2021168350A1 (en) | 2020-02-20 | 2021-08-26 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for reducing redness and increasing whiteness in eyes and other ophthalmic purposes |
| BR112022016730A2 (pt) | 2020-02-20 | 2022-11-08 | Allergan Inc | Composições farmacêuticas de agonistas de receptor alfa-2-adrenérgico e seu uso para melhorar a visão |
| CA3177005A1 (en) | 2020-04-27 | 2021-11-04 | Michael Goldstein | Methods of treating allergic conjunctivitis |
| KR20230130622A (ko) | 2021-01-11 | 2023-09-12 | 알콘 인코포레이티드 | 점탄성 전달을 위한 시스템 및 방법 |
| CN115607741B (zh) * | 2022-09-08 | 2023-11-24 | 西安德诺海思医疗科技有限公司 | 一种青光眼外科手术用复合生物材料及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3749776A (en) | 1970-08-28 | 1973-07-31 | Allergan Pharma | Method for blocking prostaglandin activity |
| US5166331A (en) | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
| US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US5516522A (en) | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
| US5972326A (en) | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
| US5612027A (en) | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
| US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5994309A (en) | 1997-07-25 | 1999-11-30 | Angstrom Pharmaceuticals, Inc. | Anti-invasive and anti-angiogenic compositions and methods |
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| CA2402405C (en) | 2000-07-14 | 2008-02-12 | Allergan Sales, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| WO2002058730A2 (en) | 2000-11-01 | 2002-08-01 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
| US6699493B2 (en) | 2000-11-29 | 2004-03-02 | Oculex Pharmaceuticals, Inc. | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7799326B2 (en) * | 2001-09-24 | 2010-09-21 | Mount Sinai School Of Medicine | Methods and compositions for cathespin k complex-mediated disorders |
| BR0315304A (pt) | 2002-11-06 | 2005-08-16 | Alza Corp | Formulações com depósito para liberação controlada |
| US20040253293A1 (en) * | 2003-06-16 | 2004-12-16 | Afshin Shafiee | Rate controlled release of a pharmaceutical agent in a biodegradable device |
| US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20090148527A1 (en) | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| US20120283232A9 (en) | 2003-11-12 | 2012-11-08 | Zhengjun Wang | Process for making a pharmaceutical composition |
| WO2005072701A1 (en) | 2004-01-20 | 2005-08-11 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US20060182781A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US7589057B2 (en) | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
| US20090082321A1 (en) | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Steroid containing drug delivery systems |
| US20070293873A1 (en) | 2006-06-19 | 2007-12-20 | Allergan, Inc. | Apparatus and methods for implanting particulate ocular implants |
| US20080097335A1 (en) | 2006-08-04 | 2008-04-24 | Allergan, Inc. | Ocular implant delivery assemblies |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US8846073B2 (en) | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
| US8231892B2 (en) * | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
| EP2288385A2 (en) | 2008-04-16 | 2011-03-02 | Allergan, Inc. | Combination therapy for glaucoma |
| EP2296621A1 (en) | 2008-05-20 | 2011-03-23 | Yale University | Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use |
| US20100104654A1 (en) * | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US8545554B2 (en) | 2009-01-16 | 2013-10-01 | Allergan, Inc. | Intraocular injector |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| KR102337046B1 (ko) * | 2010-01-22 | 2021-12-08 | 알러간, 인코포레이티드 | 전방내 서방성 치료제 이식물 |
| US20130071349A1 (en) | 2010-03-02 | 2013-03-21 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
| EP2585071A1 (en) * | 2010-06-28 | 2013-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical composition for use in the treatment of glaucoma |
| WO2012149278A1 (en) | 2011-04-29 | 2012-11-01 | Allergan, Inc. | Sustained release latanoprost implant |
-
2011
- 2011-01-21 KR KR1020207017535A patent/KR102337046B1/ko not_active Expired - Fee Related
- 2011-01-21 AU AU2011207281A patent/AU2011207281B2/en active Active
- 2011-01-21 CN CN201710411369.5A patent/CN107184544A/zh active Pending
- 2011-01-21 CN CN2011800149985A patent/CN102821753A/zh active Pending
- 2011-01-21 RU RU2012133880/15A patent/RU2565445C2/ru active
- 2011-01-21 ES ES11701723.6T patent/ES2561083T3/es active Active
- 2011-01-21 BR BR112012018134-3A patent/BR112012018134B1/pt active IP Right Grant
- 2011-01-21 JP JP2012550135A patent/JP5809169B2/ja active Active
- 2011-01-21 ES ES15191632.7T patent/ES2658175T3/es active Active
- 2011-01-21 KR KR1020127021839A patent/KR101911960B1/ko not_active Expired - Fee Related
- 2011-01-21 EP EP15191632.7A patent/EP3085358B1/en active Active
- 2011-01-21 CA CA2787514A patent/CA2787514C/en active Active
- 2011-01-21 KR KR1020187030084A patent/KR20180117211A/ko not_active Ceased
- 2011-01-21 EP EP17001789.1A patent/EP3320892A1/en not_active Withdrawn
- 2011-01-21 US US13/011,467 patent/US8647659B2/en active Active
- 2011-01-21 WO PCT/US2011/021971 patent/WO2011091205A2/en not_active Ceased
- 2011-01-21 DK DK15191632.7T patent/DK3085358T3/en active
- 2011-01-21 DK DK11701723.6T patent/DK2525776T3/en active
- 2011-01-21 EP EP11701723.6A patent/EP2525776B1/en active Active
- 2011-01-21 KR KR1020207007048A patent/KR102126007B1/ko active Active
-
2013
- 2013-09-19 US US14/031,657 patent/US9061065B2/en active Active
-
2015
- 2015-06-22 US US14/746,438 patent/US9504696B2/en active Active
-
2016
- 2016-11-28 US US15/362,197 patent/US10278919B2/en active Active
-
2019
- 2019-05-06 US US16/403,965 patent/US20190254965A1/en not_active Abandoned
- 2019-12-18 US US16/718,640 patent/US20200121593A1/en not_active Abandoned
-
2020
- 2020-10-23 US US17/079,148 patent/US20210169780A1/en not_active Abandoned
-
2023
- 2023-08-21 US US18/236,215 patent/US20240148643A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518049A5 (enExample) | ||
| RU2012133880A (ru) | Внутрикамерные имплантаты с пролонгированным высвобождением терапевтического агента | |
| US9943404B2 (en) | Intraocular cell migration inhibition system | |
| JP2021502366A5 (enExample) | ||
| US8551167B2 (en) | Intraocular implant cell migration inhibition system | |
| WO2010059214A3 (en) | Biocompatible biodegradable intraocular implant system | |
| SI3062775T1 (en) | Intraocular implants containing prostamide and methods for their use | |
| JP2016172080A (ja) | 形状記憶ポリマー眼内レンズ | |
| Argento et al. | Optic capture of the AcrySof intraocular lens in pediatric cataract surgery | |
| McNab | Hydroxyapatite orbital implants Experience with 100 cases | |
| EP3104851A1 (en) | Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration | |
| Werner et al. | Evolution of intraocular lens implantation | |
| Lee et al. | The efficacy of an acrylic intraocular lens surface modified with polyethylene glycol in posterior capsular opacification | |
| Pinsard et al. | Neodymium: YAG laser treatment of late capsular block syndrome | |
| Rosen et al. | Endocapsular cataract extraction | |
| Akaishi et al. | Multifocal intraocular lens optic anteriorization capture to correct residual refractive error | |
| Shrestha | Cataract surgery in children: Controversies and practices | |
| Rosenthal et al. | The Artisan Iris Claw Lens for Anterior Iris Fixation | |
| Bylsma | Correction of Keratometric Astigmatism: Staar Toric IOL Refractive Lens Surgery | |
| Trivedi et al. | Primary intraocular lens implantation in infantile cataract surgery | |
| Bhullar et al. | July consultation# 4 | |
| Foam-Covered | Case 160: Double Folds | |
| Falavarjani et al. | Fibrin glue–assisted sutureless scleral fixation | |
| RU2339352C1 (ru) | Способ имплантации заднекамерной интраокулярной линзы | |
| Masnec et al. | Cataract Surgery |